Dariusz Śladowski

Dr. Dariusz Śladowski

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1993 in Journal of Immunological Methods
Verified
Journal Article
Closed access
Dariusz ŚladowskiDariusz Śladowski
Dariusz Śladowski
SSSarah J. Steer
Sarah J. Steer
RCRichard H. Clothier
Richard H. Clothier
MBMichael Balls
Michael Balls

1 June 1998 in Toxicology in Vitro
Verified
Journal Article
Closed access
HSH. Spielmann
H. Spielmann
MBM. Balls
M. Balls
JDJ. Dupuis
J. Dupuis
WPW.J. Pape
W.J. Pape
GPG. Pechovitch
G. Pechovitch
PBP. Brantom
P. Brantom

27 March 2007 in Transplantation
Verified
Journal Article
Closed access
INIreneusz Nawrot
Ireneusz Nawrot
BWBogdan Woźniewicz
Bogdan Woźniewicz
TTTadeusz Tołłoczko
Tadeusz Tołłoczko
ASAndrzej Sawicki
Andrzej Sawicki
AGAndrzej Górski
Andrzej Górski
JSJacek Szmidt
Jacek Szmidt
Hypoparathyroidism is a well-known consequence of extensive thyroid and parathyroid surgery. Allotransplantation of cultured parathyroid cells can be considered as an alternative to vitamin D3 and calcium supplementation in treatment of hypoparathyroidism. We present the long-term allotransplant activity in 85 patients who had undergone cellular allotransplantation for surgical hypoparathyroidism. Also, a modified technique to prepare parathyroid explants is described for obtaining a new nonimmunogenic cell population. From March 1990 to December 2004, 85 patients underwent 116 allotransplantations of cultured parathyroid cells. Mean recipient age was 46.2+/-11.1 years. Donors were selected from patients undergoing parathyroidectomy for secondary and tertiary hyperparathyroidism. After 6 weeks of cultivation and freezing, the parathyroid cells decreased their normal human leukocyte antigen (HLA) class I ABC expression and were free of HLA class II positive cells. The viability of cultured cells was 95.15+/-2.94%. Eighty-five patients underwent primary allotransplantation. Of these, 25 patients subsequently underwent a repeat procedure. In six cases, the parathyroid cells were obtained from the same donor and in 19 cases from a different donor. For all patients, the mean cellular allograft survival was 6.35+/-13.08 months. In 64 patients (55.1%), the allografts retained their endocrine function for more than 2 months. The present study has shown that in some patients parathyroid cell allotransplantation may be considered a method of treatment for permanent hypoparathyroidism after thyroid surgery. Graft function and/or survival did not depend on the baseline viability or secretory activity of cultured cells used for transplantation.

1 September 2017 in Human Gene Therapy Clinical Development
Verified
Journal Article
Closed access
TBTomáš Boráň
Tomáš Boráň
MMMargarida Menezes-Ferreira
Margarida Menezes-Ferreira
IRIlona Reischl
Ilona Reischl
PCPatrick Celis
Patrick Celis
NFNicolas Ferry
Nicolas Ferry
PSPaula Salmikangas
Paula Salmikangas
The research and development of advanced therapy medicinal products (ATMPs) has been active in Europe and worldwide during recent years. Yet, the number of licensed products remains low. The main expected legal change in the near future in the European Union (EU) concerns the regulation on clinical trials (536/2014), which will come into force in 2018. With this new framework, a more harmonized and swift process for approval of clinical trials is anticipated, which is expected to support the entry of new innovations into the EU market. A survey on ATMPs in clinical trials during 2010–2015 in the EU was conducted in order to study the trends of ATMP development since the earlier survey published in 2012. According to the results, the number of clinical trials using ATMPs is slowly increasing in the EU. Yet, the focus is still in early development, and the projects are mainly carried out by small and medium-sized enterprises, academia, and hospitals. Oncology is the main area of clinical development. Yet, the balance between cell-based products and gene therapy medicinal products in this area may be changing in the future due to the new T-cell technologies. Many limitations and challenges are identified for ATMP development, requiring proportionate regulatory requirements. On the other hand, for such a novel field, the developers should be active in considering possible constraints and actively engage with authorities to look for solutions. This article provides up to-date information on forthcoming regulatory improvements and discusses the main challenges hampering the commercialization of ATMPs in the EU.

25 February 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EWEwa Wilczek
Ewa Wilczek
RRRobert Rzepko
Robert Rzepko
DNDominika Nowis
Dominika Nowis
MLMagdalena Legat
Magdalena Legat
JGJakub Golab
Jakub Golab
GWGrzegorz Wilczynski
Grzegorz Wilczynski
A soluble complement inhibitor factor H (FH) and its splice variant factor H‐like protein (FHL) have been recently discovered to play a major role in malignant cell escape from complement‐mediated cytotoxicity in lung‐, ovarian‐ and glia‐derived neoplasms. The role of FH in colon cancer has not yet been examined. Here, we studied immunocytochemically FH/FHL expression in tumor samples derived from 40 patients, with both primary colon adenocarcinoma and metastatic foci in the liver. FH/FHL immunoreactivity was present in stroma of both primary and metastatic tumors, in virtually all patients. The cellular immunoreactivity was observed infrequently. Importantly, when analyzed quantitatively, FH/FHL immunoreactivity was significantly increased in liver metastases when compared with the primary sites. In addition, we have analyzed FH and FHL expression in 5 colon cancer cell lines: SW480, SW620, HCT116, HT‐29 and Lovo. FH mRNA and FH secretion were observed in SW620 and HT‐29 cells, whereas FHL was produced only by HT‐29 cell‐line. By confocal and electron microscopy, FH immunoreactivity was associated with the plasma membrane and intracellular vesicular structures. Finally, we have analyzed the role of FH in the susceptibility of SW620 colon cancer cells to complement‐mediated damage. When FH function was blocked, using specific antibody, the cells became more susceptible to lysis. Taken together, our results suggest an important role of FH/FHL in colon cancer cells defense against complement‐mediated cytotoxicity, and in metastatic process.

Verified
Journal Article
Open access
PDF file
Wojciech Michał GlinkowskiWojciech Michał Glinkowski
Wojciech Michał Glinkowski
GGGrzegorz Gut
Grzegorz Gut
Dariusz ŚladowskiDariusz Śladowski
Dariusz Śladowski
Background: Platelet-rich plasma (PRP) is increasingly utilized for managing knee osteoarthritis (KOA), yet its clinical value remains debated due to the variability in preparation protocols and outcome measures. Methods: This narrative review synthesizes current evidence from 40 high-quality studies published between 2013 and March 2025, including randomized controlled trials, systematic reviews, and meta-analyses. The biological mechanisms, clinical effectiveness, safety, and implementation challenges of PRP therapy in KOA are examined. Results: PRP injections—particularly leukocyte-poor PRP—demonstrate superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids, especially in patients with mild to moderate KOA (Kellgren–Lawrence grades I–III). However, heterogeneity in PRP formulations (platelet/leukocyte content and activation protocols), injection regimens, and follow-up durations limits direct comparability across studies. Evidence from high-quality placebo-controlled trials shows inconsistent long-term benefits, with some failing to demonstrate superiority over saline beyond 6–12 months. The GRADE assessment rates the overall certainty of evidence as moderate. PRP appears safe, with few adverse events reported, but remains costly and variably reimbursed. Guidelines from major societies remain cautious or inconclusive. Conclusions: PRP is a promising, safe, and well-tolerated option for early to moderate KOA. However, the standardization of preparation protocols, patient selection criteria, and outcome reporting is essential to improve comparability and guide clinical practice.